Gemcitabine (G) plus cisplatin (C) is a highly active regimen in first-line treatment of metastatic breast cancer (MBC): Results of a multicenter phase II trial

被引：0
|
作者：
Fuentes, H
Calderillo, G
Alexander, F
Ramirez, M
Avila, E
Perez, L
Aguirre, C
机构：
[1] Inst Nacl Cancerol, SSA, Mexico City, DF, Mexico
[2] Hosp Gen Occidente Seguro Social, SSA, Oncol Serv, Guadalajara, Jalisco, Mexico
[3] IMSS, Unidad Morelos 1, Cuernavaca, Morelos, Mexico
[4] Ctr Med Potosi, Oncol & Radiotherapy Serv, San Luis Potosi, Mexico
[5] Clin ISSSTE, Oncol Serv, Ensenada, Baja California, Mexico
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
10.1016/S0959-8049(02)80216-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
130
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [1] Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial
    Karthaus, Meinolf
    Poddubnaya, Irina
    Churilova, L.
    Khazanov, R.
    Veremeychuk, T.
    Rumyantzeva, E.
    Garin, M.
    Brichkova, O.
    Heinrich, Bernhard
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial.
    Karthaus, M.
    Poddubnaya, I.
    Churilova, L.
    Khasanov, R.
    Veremeychuk, T.
    Rumyantseva, E.
    Garin, M.
    Brichkova, O.
    Heinrich, B.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [3] Results of first-line weekly paclitaxel (P) plus gemcitabine (G) in metastatic breast cancer (MBC): An AERO phase II trial
    Mousseau, M.
    Serin, D.
    Petit, T.
    Priou, F.
    Zelek, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Final results of first-line weekly paclitaxel plus gemcitabine in metastatic breast cancer (MBC): an AERO phase II trial
    Mousseau, M.
    Serin, D.
    Goubely-Brewer, Y.
    Petit, T.
    Priou, F.
    Zelek, L.
    BULLETIN DU CANCER, 2007, 94 (06) : 569 - 570
  • [5] Phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for metastatic urothelial carcinoma
    Gartrell, Benjamin Adam
    Hahn, Noah M.
    Hutson, Thomas E.
    Sonpavde, Guru
    Hauke, Ralph J.
    Starodub, Alexander
    Small, Alexander C.
    Tsao, Che-Kai
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer:: Results of a multicenter phase II study
    Palmeri, S
    Vaglica, M
    Spada, S
    Filippelli, G
    Farris, A
    Palmeri, L
    Massidda, B
    Misino, A
    Ferraù, F
    Comella, G
    Leonardi, V
    Condemi, G
    Mangiameli, A
    De Cataldis, G
    Macaluso, MC
    Cajozzoo, M
    Iannitto, E
    Danova, M
    ONCOLOGY, 2005, 68 (4-6) : 438 - 445
  • [7] Gemcitabine (G) and Doxorubicin (DXR) as first-line treatment of metastatic breast cancer (MBC): Preliminary results.
    Bensalem, A
    Bouzid, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [8] A phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer (MBC): Interim safety results
    Brufsky, A. M.
    Hoelzer, K. L.
    Keaton, M. R.
    Beck, J. T.
    Krill-Jackson, E.
    Wang, Y.
    Hu, S.
    Vaughn, L. G.
    Shonukan, O. O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) plus /- Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC)
    Schwartzberg, L. S.
    Hermann, R.
    Blakely, J.
    Richey, S. S.
    Tauer, K. W.
    Childs, B. H.
    CANCER RESEARCH, 2010, 70
  • [10] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    Cappuzzo, F
    Mazzoni, F
    Gennari, A
    Donati, S
    Salvadori, B
    Orlandini, C
    Cetto, GL
    Molino, A
    Galligioni, E
    Mansutti, M
    Tumolo, S
    Lucentini, A
    Valduga, F
    Bartolini, S
    Crinò, L
    Conte, PF
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 31 - 35
12345